睿知中国疾病研究地图
候选清单0

正在招募食管鳞状细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07162506,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed, resectable locally advanced ESCC, defined as cT1N1-3M0 or cT2-4aN0-3M0 according to the AJCC 8th edition, with cCR or PR achieved after 2-3 cycles of induction chemoimmunotherapy consisting of a permitted PD-1 inhibitor combined with a taxane and a platinum agent.

    入选标准第 3 条

  3. Patients of childbearing potential must use a medically approved contraceptive method (such as intrauterine device, contraceptive pills, or condoms) during the study treatment period and within 6 months after the end of the study treatment; serum Human Chorionic Gonadotropin (HCG) or urine HCG test must be negative within 72 hours before study enrollment; and must not be breastfeeding.

    入选标准第 16 条

    Active tuberculosis infection detected by history or CT examination, or history of active tuberculosis infection within 1 year before enrollment or more than 1 year previously without regular treatment;

    排除标准第 17 条

    Presence of abnormal sodium, potassium, and calcium laboratory test values greater than grade 1 within 2 weeks prior to enrollment that do not improve with treatment;

    排除标准第 19 条

    Previously diagnosed with any other malignancy within 5 years before the first use of the investigational drug, except for malignancies with low risk of metastasis and death (5-year survival rate>90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.

    排除标准第 21 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

    入选标准第 5 条

  5. Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L;

    入选标准第 8 条

    Platelets ≥ 80×10\^9/L;

    入选标准第 9 条

    Hemoglobin ≥ 9 g/dL;

    入选标准第 10 条

    Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or ALP ≤ 2.5 × ULN;

    入选标准第 12 条

    Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min;

    入选标准第 13 条

    International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5× ULN (subjects on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, and with INR within the expected therapeutic range of the anticoagulant can be screened);

    入选标准第 14 条

  6. Presence of measurable and/or non-measurable lesions as defined by Japanese Classification of Esophageal Cancer (12th Edition);

    入选标准第 4 条

  7. Diagnosis of immunodeficiency, including positive HIV test, other acquired/congenital immunodeficiency diseases, organ transplantation and allogeneic bone marrow transplantation;

    排除标准第 13 条

    Active hepatitis B infection (HBV DNA >2000 IU/mL) or active hepatitis C infection with detectable HCV RNA;

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07162506,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Volunteered to participate, cooperated with follow-up visits.
  2. Aged 18 - 75 years (inclusive), male or female.
  3. Histologically confirmed, resectable locally advanced ESCC, defined as cT1N1-3M0 or cT2-4aN0-3M0 according to the AJCC 8th edition, with cCR or PR achieved after 2-3 cycles of induction chemoimmunotherapy consisting of a permitted PD-1 inhibitor combined with a taxane and a platinum agent.
  4. Presence of measurable and/or non-measurable lesions as defined by Japanese Classification of Esophageal Cancer (12th Edition);
  5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  6. Life expectancy ≥ 3 months.
  7. The function of major organs meets the following requirements:
  8. Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L;
  9. Platelets ≥ 80×10\^9/L;
  10. Hemoglobin ≥ 9 g/dL;
  11. Serum albumin ≥ 2.8 g/dL;
  12. Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or ALP ≤ 2.5 × ULN;
  13. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min;
  14. International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5× ULN (subjects on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, and with INR within the expected therapeutic range of the anticoagulant can be screened);
  15. Comprehensive baseline staging evaluation prior to induction chemoimmunotherapy, including esophagogastroduodenoscopy with biopsy and/or EUS, contrast-enhanced CT of the neck, chest, and upper abdomen, MRI in patients without contraindications, and an upper gastrointestinal contrast study. PET/CT may be performed when clinically indicated and feasible.
  16. Patients of childbearing potential must use a medically approved contraceptive method (such as intrauterine device, contraceptive pills, or condoms) during the study treatment period and within 6 months after the end of the study treatment; serum Human Chorionic Gonadotropin (HCG) or urine HCG test must be negative within 72 hours before study enrollment; and must not be breastfeeding.

排除标准:Exclusion Criteria:

  1. Prior surgery for esophageal cancer;
  2. Esophageal fistulae due to infiltration of the primary tumor;
  3. Risk of gastrointestinal bleeding, esophageal fistula or esophageal perforation;
  4. Poor nutritional status, weight loss of ≥10% in the previous 2 months, with no significant improvement after nutritional intervention;
  5. Major surgery or severe trauma within 4 weeks before formal enrollment;
  6. Uncontrollable pleural effusion, pericardial effusion, or ascites that requires repeated drainage;
  7. Received or receiving any of the following treatments in the past:
  8. Radiotherapy or targeted therapy;
  9. Participation in a study of an investigational agent or device within 4 weeks before the first dose of study treatment;
  10. Use of systemic corticosteroids at a dose >10 mg/day prednisone equivalent or other systemic immunosuppressive therapy within 2 weeks before formal enrollment, except for inhaled or topical corticosteroids, physiologic hormone-replacement therapy, and short-term corticosteroids used for prophylaxis or treatment of allergic reactions, nausea, or vomiting;
  11. Receipt of a live vaccine or antitumor vaccine within 4 weeks before formal enrollment;
  12. Any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonitis, uveitis, enteritis, hepatitis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Except for patients with vitiligo or those who had asthma or allergies in childhood but did not need any intervention as adults; patients with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone and type I diabetes mellitus treated with stable doses of insulin may be included;
  13. Diagnosis of immunodeficiency, including positive HIV test, other acquired/congenital immunodeficiency diseases, organ transplantation and allogeneic bone marrow transplantation;
  14. Diagnosis of uncontrolled cardiac clinical symptoms or disease such as: a. NYHA II or above heart failure; b. unstable angina; c. myocardial infarction within 1 year; d. clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;
  15. Severe infections (CTCAE > grade 2), such as severe pneumonia requiring hospitalisation, bacteraemia, infectious co-morbidities, etc., within 4 weeks before formal enrollment; Baseline chest imaging suggestive of active lung inflammation, signs and symptoms of infection requiring oral or intravenous antibiotic treatment within 2 weeks before the first use of study treatment, except for prophylactic antibiotic use;
  16. History of interstitial lung disease or non-infectious pneumonia, or pulmonary insufficiency ≥ grade 3 as confirmed by pulmonary function tests;
  17. Active tuberculosis infection detected by history or CT examination, or history of active tuberculosis infection within 1 year before enrollment or more than 1 year previously without regular treatment;
  18. Active hepatitis B infection (HBV DNA >2000 IU/mL) or active hepatitis C infection with detectable HCV RNA;
  19. Presence of abnormal sodium, potassium, and calcium laboratory test values greater than grade 1 within 2 weeks prior to enrollment that do not improve with treatment;
  20. Known hypersensitivity or contraindication to camrelizumab, nab-paclitaxel, carboplatin, or any component of the protocol-defined study treatments;
  21. Previously diagnosed with any other malignancy within 5 years before the first use of the investigational drug, except for malignancies with low risk of metastasis and death (5-year survival rate>90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.
  22. As judged by the investigator, the subject has other factors that may lead to forced termination of the study midway.

引自 ClinicalTrials.gov, NCT07162506, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07162506,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07162506